Documentation of psoriasis in routine care - expert consensus on a German data set.

Background And Objectives: Documenting patient data in psoriasis clinical practice can improve care, but standardized and transparent documentation is rare. The current project aimed to develop a data set for the documentation of psoriasis in daily practice.

Material And Methods: In four online Delphi rounds and one in-person meeting, 27 psoriasis experts allocated variables to a standard, an optimal and an optional data set.

Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review.

Brodalumab, a recombinant fully human monoclonal immunoglobulin IgG2 antibody with high affinity to human interleukin (IL)-17RA, is approved for the treatment of moderate-to-severe plaque psoriasis. In controlled clinical trials, brodalumab 210 mg administered by subcutaneous injection at weeks 0, 1, and 2, then 210 mg every 2 weeks, produced a rapid onset and sustained clinical response. Consistently, >80% of patients achieved PASI-75 and efficacy was maintained for >2 years.

Clinical assessment of a foam dressing containing growth factor-enhancing hydrated polyurethanes.

Objective: This study assesses a novel dressing concept in venous leg ulcer (VLU) patients. It is based on boosting endogenous growth factor activities synthesised by functional granulation tissue.

Methods: Patients received treatment for eight weeks with a hydrated polyurethane-containing foam dressing plus concomitant compression therapy.